Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HIV RT

Financiado

Cerrado

Mechanics of HIV Reverse Transcriptase

The oncogenic human immunodeficiency virus (HIV) currently infects an estimated 33 million individuals and has claimed more than 25 million lives. The primary treatment of HIV consists of a cocktail of several classes of antiretro... ver más

31/01/2016

TU Delft

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

TECHNISCHE UNIVERSITEIT DELFT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-01-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TU Delft

0.00€ | Lider

Proyectos interesantes

BICEPSvsHIV

Medical Technol...

Data Science

164K€ Cerrado

HIVPROTMOLMECH

Medical Technol...

Data Science

147K€ Cerrado

HIV ACE

Medical Technol...

Data Science

5M€ Cerrado

BFU2012-30770

Medical Technol...

Data Science

115K€ Cerrado

BIO2010-20696

Medical Technol...

Data Science

97K€ Cerrado

HIVEVO

Medical Technol...

Data Science

1M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

TECHNISCHE UNIVERSITEIT DELFT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The oncogenic human immunodeficiency virus (HIV) currently infects an estimated 33 million individuals and has claimed more than 25 million lives. The primary treatment of HIV consists of a cocktail of several classes of antiretroviral drugs targeting various components of the HIV virus. The most utilized target of antiretroviral drugs is reverse transcriptase (RT), an enzyme that transforms the viral genome from ssRNA to dsDNA. Unfortunately, significant gaps remain in our understanding of how RT functions. Using single molecule techniques, I have previously shown that the orientation of RT while associated with nucleic acids is highly dynamic and characterized by both flipping and sliding transitions. These transitions are associated with processing of the poly-purine tract (PPT) sequence, the rapid targeting of RT to the ends of long regions of double stranded nucleic acids, and strand displacement synthesis. In this grant, I propose to develop additional single molecule assays to further study the dynamic interactions of RT with physiologically relevant nucleic acid substrates. These new assays will allow my lab to address specific questions relevant to the understanding of this key enzyme. First, we will determine the mechanisms of the flipping and sliding transitions and test whether these transitions are required for the successful completion of key steps in the reverse transcription reaction. Second, we will probe the detailed mechanism of strand displacement synthesis and determine the energetic contacts RT uses to stabilize the annealed primer strand. Finally, we will also measure the effects of antiretroviral drugs in preventing the completion of individual steps of the reverse transcription process to identify potentially novel mechanisms of inhibition. Taken together, this research offer fundamental insights into protein and nucleic acid interactions and help to define the next generation of anti-HIV drugs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores